Due to the noted effect of ALK TKI combination treatments with both miR-1304-5p mimics or lonafarnib in NB cells, we further investigated this regulatory axis in 3 ALK mutant, high-risk NB PDXs: PDX FELIX—COG-N-426x (ALKF1245C; MYCN WT), COG-N-415 (ALKF1174L; MYCN amplified) and COG-N-557 (ALKF1245L; MYCN amplified) (Fig. 6A–F, Supplementary Fig. 14). Here, ALK is linked to neuroblastoma.